Synopsis:
Torrent Pharma announced that it is introducing MSD (a trade name of Merck & Co., Inc, Kenilworth, New Jersey, USA) and Ridgeback’s molnupiravir under the brand name Molnutor in India.
Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD, granting rights to Torrent Pharma for manufacturing, distribution and marketing of molnupiravir in more than 100 low-and middle-income markets including India for treatment of Covid-19.
Torrent Pharma to launch Molnupiravir under the Brand Name Molnutor in India
The Drugs Controller General of India (DCGI), based on the review of clinical data of molnupiravir has approved the drug for the treatment of Covid-19 in adults for restricted emergency use in India.
Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] for the treatment of mild-to-moderate Covid-19 in adults.
Commenting on the launch, Aman Mehta (executive director – India) said: “We are pleased to partner with MSD to bring molnupiravir to patients across India. Molnupiravir will be an important addition to our healthcare system’s ammunition in the fight against Covid-19.”
About Torrent Pharma
Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, owned by Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Drug firm Torrent Pharmaceuticals on 23 July 2019 reported a 32.51 percent rise in its consolidated net profit to Rs 216 crore for the quarter ended 30 June, mainly on account of robust sales in most geographies
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)
